Respiratory pharmacology is governed by receptor-specific mechanisms that modulate vascular permeability, airway tone, and mucus viscosity through antagonism or agonism at histamine (H1), adrenergic alpha, muscarinic M3, endothelin-ETa, nitric oxide-cGMP-PKG/calcium pathways, phosphodiesterase 5, prostacyclin receptors, and the nucleus tractus solitarius. The core theoretical principles involve using H1 antagonists to block capillary dilation, bronchoconstriction, and nociceptor activation; alpha-adrenergic agonists to induce nasal vasoconstriction via norepinephrine availability; direct vasodilators (prostacyclins) or ETa/PDE5 inhibitors to reduce pulmonary vascular resistance in hypertension; guaifenesin for mucokinetic effects; acetylcysteine for disulfide bond disruption of mucus; and dextromethorphan as an NMDA antagonist at the brainstem cough center. This domain falls under Pulmonology, specifically targeting systemic allergic inflammation, upper airway congestion, pulmonary vascular remodeling, expectoration, antitussive suppression, and diagnostic bronchoprovocation within respiratory pathophysiology.
Respiratory pharmacology is governed by receptor-specific mechanisms that modulate vascular permeability, airway tone, and mucus viscosity through antagonism or agonism at histamine (H1), adrenergic …